San Antonio, TX – October 15, 2026 Adriana Baker, a MD PhD candidate in the laboratory of EtiraRx founder Dr. Ratna Vadlamudi at UT Health San Antonio, presented exciting new findings at the 2026 San Antonio Liver Cancer Symposium, held…
https://etira.life/wp-content/uploads/2026/10/blog_square.jpg10801080Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2026-10-16 10:25:192026-10-19 17:53:36ERX-315 Sensitizes Liver Cancer to PARP Inhibitors
San Antonio, TX – October 12, 2026 We are pleased to share our new paper in Cancer Research Communications, showing that ERX-208, Etira’s LIPA-targeting compound, disrupts DNA repair in ovarian cancer cells by inducing sustained endoplasmic…
https://etira.life/wp-content/uploads/2026/10/enhanced_square.png20482048Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2026-10-13 09:19:402026-10-19 17:52:25ERX-208 Disrupts DNA Repair
Dallas, TX — September 7, 2026
Etira today announced that a patient enrolled in its ongoing Phase 1 clinical trial of ERX-315 (NCT06533332) has now remained on treatment for more than one year.
The patient entered the ERX-315-101 study…
https://etira.life/wp-content/uploads/2026/04/Grok-Image-2026-09-14-at-2.22.04-PM-2.png11521712Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2026-09-07 09:35:012026-10-19 17:59:50One Year on ERX-315
San Diego, CA - April 20, 2026
Durga Paneerdoss, an undergraduate working in the laboratory of EtiraRx founder Ratna Vadlamudi received the Third Place Prize in the Margaret Foti Foundation Undergraduate Student Prize competition at the AACR…
https://etira.life/wp-content/uploads/2026/04/Durga_Paneerdoss.jpeg8181158Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2026-04-20 09:35:012026-10-19 18:01:02ERX research wins AACR award
Dallas, TX - April 14, 2026
We are pleased to announce that EtiraRx has been selected for the 2025 MassChallenge U.S. Early Stage Healthcare Cohort — a highly selective, zero-equity accelerator! This puts us alongside a global network of…
https://etira.life/wp-content/uploads/2026/04/MC-1.png25122532Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2026-04-14 15:17:312026-10-19 18:00:57Etira chosen for Mass Challenge!
San Antonio, TX - March 23, 2026 We are pleased to present our new open-access paper in Biomolecules (link here).Our paper shows activity of ERX-41 in Inflammatory breast cancer (IBC), a rare (2–4%) extremely aggressive subset of…
https://etira.life/wp-content/uploads/2026/03/1565c5da-3105-4c13-949d-0e159581542e.jpg521930Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2026-03-23 11:40:282026-10-19 18:00:52ERX-41 active in aggressive Breast Cancer
San Antonio TX, February 06, 2026Introducing ERX-208 - our supercharged ERX-41 analog for ovarian cancer!Publication in Oncogene shows the same powerful MOA of inducing uncompensated ER stress, but ERX-208 delivers dramatically higher…
https://etira.life/wp-content/uploads/2026/03/oncogene-logo-2.jpg400495Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2026-03-06 08:08:362026-03-23 18:50:50Optimization of LIPA targeting in Ovarian Cancer
Congratulations to Dr Annalisa Jenkins OBE, a member of Etira’s Board of Directors, who has been appointed an Officer of the Order of the British Empire (OBE) in The King’s New Year Honours for her contributions to the life sciences.
https://etira.life/wp-content/uploads/2026/01/Dr-Annalisa.jpg500500Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2026-01-09 08:00:542026-03-06 07:50:36Etira Board Member recognized in 2026 King’s New Year Honors
San Antonio, TX – November 18, 2025. Etira Founder Professor Ratna Vadlamudi delivered a compelling, deeply personal narrative as the featured speaker at the Health Cell State of the Industry event at the Tobin Center in San Antonio.
Philadelphia, PA – July 16, 2025: In an article just published in Clinical Leader magazine entitled "How An Australia-First Strategy Cut 63% From Our R&D Spend", Etira CEO Russell Hayward explains how our strategic decision to conduct…
https://etira.life/wp-content/uploads/2025/07/australia-rd-savings-etira.jpg14501530Carlton Hoythttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngCarlton Hoyt2025-07-16 08:27:302026-01-02 10:45:53Etira CEO Featured In Clinical Leader for R&D Efficiency
Patients must be at least 18 years of age at the time of signing the informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate baseline organ function and hematologic function
Life expectancy >3 months
Exclusion criteria
Systemic anti-cancer therapy within 4 weeks of first dose of study drug
Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
Uncontrolled intercurrent illnesses
Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.
ERX-315 Sensitizes Liver Cancer to PARP Inhibitors
NewsERX-208 Disrupts DNA Repair
NewsOne Year on ERX-315
NewsERX research wins AACR award
NewsEtira chosen for Mass Challenge!
NewsERX-41 active in aggressive Breast Cancer
NewsOptimization of LIPA targeting in Ovarian Cancer
NewsEtira Board Member recognized in 2026 King’s New Year Honors
NewsEtira Founder’s Scientific Journey Highlighted
NewsEtira CEO Featured In Clinical Leader for R&D Efficiency
News